Lornoxicam

	WikiDoc Resources for Lornoxicam
Articles
Most recent articles on Lornoxicam Most cited articles on Lornoxicam Review articles on Lornoxicam Articles on Lornoxicam in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Lornoxicam Images of Lornoxicam Photos of Lornoxicam Podcasts & MP3s on Lornoxicam Videos on Lornoxicam
Evidence Based Medicine
Cochrane Collaboration on Lornoxicam Bandolier on Lornoxicam TRIP on Lornoxicam
Clinical Trials
Ongoing Trials on Lornoxicam at Clinical Trials.gov Trial results on Lornoxicam Clinical Trials on Lornoxicam at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Lornoxicam NICE Guidance on Lornoxicam NHS PRODIGY Guidance FDA on Lornoxicam CDC on Lornoxicam
Books
Books on Lornoxicam
News
Lornoxicam in the news Be alerted to news on Lornoxicam News trends on Lornoxicam
Commentary
Blogs on Lornoxicam
Definitions
Definitions of Lornoxicam
Patient Resources / Community
Patient resources on Lornoxicam Discussion groups on Lornoxicam Patient Handouts on Lornoxicam Directions to Hospitals Treating Lornoxicam Risk calculators and risk factors for Lornoxicam
Healthcare Provider Resources
Symptoms of Lornoxicam Causes & Risk Factors for Lornoxicam Diagnostic studies for Lornoxicam Treatment of Lornoxicam
Continuing Medical Education (CME)
CME Programs on Lornoxicam
International
Lornoxicam en Espanol Lornoxicam en Francais
Business
Lornoxicam in the Marketplace Patents on Lornoxicam
Experimental / Informatics
List of terms related to Lornoxicam

Lornoxicam
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy; category	Not recommended; contraindicated in months 7–9;
Routes of; administration	Oral, parenteral
ATC code	M01AC05 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	90–100%
Protein binding	99%
Metabolism	CYP2C9
Elimination half-life	3–4 hours
Excretion	2/3 hepatic, 1/3 renal
Identifiers
	IUPAC name (3E)-6-chloro-3-[hydroxy(pyridin-2-ylamino)methylene]-2-methyl-2,3-dihydro-4H-thieno[2,3-e][1,2]thiazin-4-one 1,1-dioxide;
PubChem CID	5282204;
DrugBank	DB06725 ;
ChemSpider	4445392 ;
UNII	ER09126G7A;
KEGG	D01866 ;
ChEBI	CHEBI:31783 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C13H10ClN3O4S2
Molar mass	371.8192 g/mol
3D model (JSmol)	Interactive image;
	SMILES CN1C(=C(NC2=CC=CC=N2)O)C(=O)C3=C(S1(=O)=O)C=C(S3)Cl;
(what is this?) (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Lornoxicam (INN, or chlortenoxicam; trade name Xefo, among others) is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic (pain relieving), anti-inflammatory and antipyretic (fever reducing) properties. It is available in oral and parenteral formulations.

Indications

Lornoxicam is used for the treatment of various types of pain, especially resulting from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica, and other inflammations.^[1]

Contraindications

The drug is contraindicated in patients that must not take other NSAIDs, possible reasons including salicylate sensitivity, gastrointestinal bleeding and bleeding disorders, and severe impairment of heart, liver or kidney function. Lornoxicam is not recommended during pregnancy and breastfeeding and is contraindicated during the last third of pregnancy.^[1]

Adverse effects

Lornoxicam has side effects similar to other NSAIDs, most commonly mild ones like gastrointestinal disorders (nausea and diarrhea) and headache. Severe but seldom side effects include bleeding, bronchospasms and the extremely rare Stevens–Johnson syndrome.^[1]

Interactions

Interactions with other drugs are typical of NSAIDs. Combination with vitamin K antagonists like warfarin increases the risk of bleeding. Combination with ciclosporin can lead to reduced kidney function, and to acute renal failure in rare cases. Lornoxicam can also increase the adverse effects of lithium, methotrexate and digoxin and its derivatives. The effect of diuretics, ACE inhibitors and angiotensin II receptor antagonists can be reduced, but this is only relevant in patients with special risks like heart failure. As with piroxicam, cimetidine can increase plasma levels but is unlikely to cause relevant interactions.^[2]

References

↑ ^1.0 ^1.1 ^1.2 Haberfeld, H, ed. (2009). Austria-Codex (in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 3-85200-196-X.
↑ Klopp, T, ed. (2010). Arzneimittel-Interaktionen (in German) (2010/2011 ed.). Arbeitsgemeinschaft für Pharmazeutische Information. ISBN 978-3-85200-207-1.

[AC-1] 1.0 ^1.1 ^1.2 Haberfeld, H, ed. (2009). Austria-Codex (in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 3-85200-196-X.

[Arzneimittel-Interaktionen-2] Klopp, T, ed. (2010). Arzneimittel-Interaktionen (in German) (2010/2011 ed.). Arbeitsgemeinschaft für Pharmazeutische Information. ISBN 978-3-85200-207-1.

[1]

[2]

v t e Nonsteroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA)
Pyrazolones / Pyrazolidines	Aminophenazone Ampyrone Azapropazone Clofezone Difenamizole Famprofazone Feprazone Kebuzone Metamizole Mofebutazone Morazone Nifenazone Oxyphenbutazone Phenazone Phenylbutazone Propyphenazone Sulfinpyrazone Suxibuzone^‡
Salicylates	Aspirin (acetylsalicylic acid)^# Aloxiprin Benorylate Carbasalate calcium Diflunisal Dipyrocetyl Ethenzamide Guacetisal Magnesium salicylate Methyl salicylate Salsalate Salicin Salicylamide Salicylic acid (salicylate) Sodium salicylate
Acetic acid derivatives and related substances	Aceclofenac Acemetacin Alclofenac Amfenac Bendazac Bromfenac Bumadizone Bufexamac Diclofenac Difenpiramide Etodolac Felbinac Fenclozic acid Fentiazac Indometacin Indometacin farnesil Isoxepac Ketorolac Lonazolac Oxametacin Prodolic acid Proglumetacin Sulindac Tiopinac Tolmetin Zomepirac^†
Oxicams	Ampiroxicam Droxicam Isoxicam Lornoxicam Meloxicam Piroxicam Tenoxicam
Propionic acid derivatives (profens)	Alminoprofen Benoxaprofen^† Carprofen^‡ Dexibuprofen Dexketoprofen Fenbufen Fenoprofen Flunoxaprofen Flurbiprofen Ibuprofen^# Ibuproxam Indoprofen^† Ketoprofen Loxoprofen Miroprofen Naproxen Oxaprozin Pirprofen Suprofen Tarenflurbil Tepoxalin^‡ Tiaprofenic acid Vedaprofen^‡ Zaltoprofen COX-inhibiting nitric oxide donator: Naproxcinod
N-Arylanthranilic acids (fenamates)	Azapropazone Clonixin Etofenamate Flufenamic acid Flunixin Meclofenamic acid Mefenamic acid Morniflumate Niflumic acid Tolfenamic acid Flutiazin
Coxibs	Apricoxib Celecoxib Cimicoxib^‡ Deracoxib^‡ Etoricoxib Firocoxib^‡ Lumiracoxib^† Mavacoxib^‡ Parecoxib Robenacoxib^‡ Rofecoxib^† Valdecoxib^†
Other	Aminopropionitrile Benzydamine Chondroitin sulfate Diacerein Fluproquazone Glucosamine Glycosaminoglycan Hyperforin Nabumetone Nimesulide Oxaceprol Proquazone Superoxide dismutase/Orgotein Tenidap
Items listed in bold indicate initially developed compounds of specific groups. ^#WHO-EM ^†Withdrawn drugs. ^‡Veterinary use medications.

Clinical data


AHFS/Drugs.com	International Drug Names
Pregnancy category	Not recommended; contraindicated in months 7–9
Routes of administration	Oral, parenteral
ATC code	M01AC05 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	90–100%
Protein binding	99%
Metabolism	CYP2C9
Elimination half-life	3–4 hours
Excretion	2/3 hepatic, 1/3 renal
Identifiers
IUPAC name (3E)-6-chloro-3-[hydroxy(pyridin-2-ylamino)methylene]-2-methyl-2,3-dihydro-4H-thieno[2,3-e][1,2]thiazin-4-one 1,1-dioxide
PubChem CID	5282204
DrugBank	DB06725^Y
ChemSpider	4445392^N
UNII	ER09126G7A
KEGG	D01866^Y
ChEBI	CHEBI:31783^N
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₃H₁₀ClN₃O₄S₂
Molar mass	371.8192 g/mol
3D model (JSmol)	Interactive image
SMILES CN1C(=C(NC2=CC=CC=N2)O)C(=O)C3=C(S1(=O)=O)C=C(S3)Cl
^NY (what is this?) (verify)